New EU Ovarian Cancer Diagnostic Approval Could Be A Game Changer For Agilent ...

Agilent Technologies received European regulatory approval for its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic for ovarian cancer, enhancing its position in immuno-oncology diagnostics and its collaboration with Merck across Europe.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.